Sanofi: Hemophilia A trials
The registry lists 29 Hemophilia A studies with Sanofi as lead sponsor. 4 are open to participants now and 14 have results posted.
Phase 1 6Phase 2 3Phase 3 15Phase 4 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Describe Patient REal-world FitusiRan ExpeRienceNot yet recruitingNCT07895381
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BRecruitingNCT07285460Phase 3
- Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophyRecruitingNCT06941870Phase 4
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabRecruitingNCT06145373Phase 4
- Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia ACompletedNCT04759131Phase 3Results posted
- A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia ACompletedNCT04161495Phase 3Results posted
- A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent ProphylaxisCompletedNCT03549871Phase 3Results posted
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompletedNCT03417245Phase 3Results posted
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedNCT03417102Phase 3Results posted
- A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)CompletedNCT03205163Phase 1/2Results posted
- A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)CompletedNCT03093480Phase 4Results posted
- An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or BCompletedNCT02554773Phase 1/2Results posted
- Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) ScaleCompletedNCT02502149Phase 3Results posted
- An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia ACompletedNCT02234323Phase 3Results posted
- Pharmacokinetics of rFVIIIFc at Two Vial StrengthsCompletedNCT02083965Phase 1Results posted
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia ACompletedNCT01458106Phase 3Results posted
- Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia ACompletedNCT01454739Phase 3Results posted
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia ACompletedNCT01181128Phase 3Results posted
- A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanActive, not recruitingNCT06684314
- Goal Attainment and Physical Activity in People With Hemophilia ATerminatedNCT06530030
- A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia AActive, not recruitingNCT05911763
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaActive, not recruitingNCT05662319Phase 3
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ACompletedNCT05042440Phase 1
- Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia AActive, not recruitingNCT04644575Phase 3
- Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BCompletedNCT03974113Phase 2/3
- Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXCompletedNCT03754790Phase 3
- Fc factOrs and Real-World hemophiliA Patient-ReporteD OutcomesTerminatedNCT02392156
- A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B PatientsCompletedNCT02035605Phase 1
- Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia ACompletedNCT01027377Phase 1